Standard BioTools Inc. Payments of Loan Costs
Standard BioTools Inc. (LAB) reported Payments of Loan Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfLoanCosts · last filed 2026-03-16
- Standard BioTools Inc. payments of loan costs for the quarter ending 2025-12-31 was $0.00.
- Standard BioTools Inc. payments of loan costs for the quarter ending 2025-09-30 was $0.00.
- Standard BioTools Inc. payments of loan costs for the quarter ending 2025-06-30 was $0.00.
- Standard BioTools Inc. payments of loan costs for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. payments of loan costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Standard BioTools Inc. payments of loan costs for fiscal 2024 was $545.00K.
- Standard BioTools Inc. payments of loan costs for fiscal 2023 was $0.00.
| Period end | Payments of Loan Costs 3 month | Payments of Loan Costs 6 month | Payments of Loan Costs 9 month | Payments of Loan Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $0.00 10-K · filed 2026-03-16 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | $0.00 10-Q · filed 2025-08-15 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $0.00 derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $0.00 derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $545.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $545.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | $545.00K 10-Q · filed 2025-08-15 | ||
| 2024-03-31 | $545.00K 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |